High levels of C-reactive protein, a marker of systemic inflammation, at the onset of back pain can help predict which…
Articles by Iqra Mumal, MSc
The presence of a specific genetic marker called HLA-B27 in Caucasian ankylosing spondylitis patients is related to earlier disease onset and higher…
Patients with ankylosing spondylitis treated with anti-rheumatic drugs or anti-tumor necrosis therapy are not more likely to develop infections compared…
Patients with ankylosing spondylitis have differences in the diversity of the fungi and bacterial populations that reside in the…
Anti-TNF therapy and other biologics — often used for the treatment of inflammatory arthritis — partially protect ankylosing spondylitis…
Inhibiting IL-23, a molecule involved in inflammation, was not found to be clinically meaningful to treat ankylosing spondylitis, according…
Treatment with Eli Lilly’s monoclonal antibody Taltz (ixekizumab) significantly improved the signs and symptoms of ankylosing spondylitis in patients participating in a Phase 3…
Social media data has allowed scientists to examine ankylosing spondylitis patients’ knowledge, attitudes, and beliefs regarding biologic therapies. The…
Ankylosing spondylitis patients who receive tailored, personalized services, such as care coach calls, have a higher probability of achieving…
Patients with ankylosing spondylitis are more likely to develop a lung disorder known as chronic obstructive pulmonary disease (COPD)…